Business Desk :
Summit Technopolis, a subsidiary of Summit Group, handed over the possession of 25 acres of land to Oryx Bio-tech for setting up plasma fractionation plant within six months after tripartite agreement signing. Prior to handing over, Summit Technopolis has completed extensive land improvement with additional Tk5.14 crore investment to meet the critical requirements for the development of the country’s first biotechnology plant. This biotech investment in Bangladesh with a valuation of $300 million will be built at the Block II of Bangabandhu Hi-Tech City, Gazipur, said a press release.
Oryx Bio-tech is a subsidiary of Oryx Biotech Holdings based in China and it is expected that about 2,000 high-value science graduates will be employed when the plant is expected to commence operation in 2023, subject to obtaining all the regulatory permissions.
Hosne Ara Begum, Managing Director of Bangladesh Hi-Tech Park Authority (BHTPA), Abu Reza Khan, Managing Director of Summit Technopolis (a subsidiary of Summit Group) and Kazi Shakil, Chairman of Oryx Biotech, handed over the document after signing the tripartite agreement at BHTPA head office in the city on Sunday. Under the deal, Oryx Biotech will set up plasma fractionation plant at Bangabandhu Hi-Tech City in Gazipur.
ANM Shafiqul Islam, Director, Md. Mahfuzul Kabir, Deputy Director of Bangladesh Hi-Tec Park Authority (BHTPA), and other senior officials were also present at the handover ceremony at the ICT Tower in city’s Agargaon area.
